299 related articles for article (PubMed ID: 37731164)
1. Mechanisms and Clinical Significance of Pharmacokinetic Drug Interactions Mediated by FDA and EMA-approved Hepatitis C Direct-Acting Antiviral Agents.
Murray M
Clin Pharmacokinet; 2023 Oct; 62(10):1365-1392. PubMed ID: 37731164
[TBL] [Abstract][Full Text] [Related]
2. Management of drug interactions with direct-acting antivirals in Dutch HIV/hepatitis C virus-coinfected patients: adequate but not perfect.
Smolders EJ; Smit C; de Kanter C; Dofferhoff A; Arends JE; Brinkman K; Rijnders B; van der Valk M; Reiss P; Burger DM;
HIV Med; 2018 Mar; 19(3):216-226. PubMed ID: 29194939
[TBL] [Abstract][Full Text] [Related]
3. Direct-acting antivirals for chronic hepatitis C.
Jakobsen JC; Nielsen EE; Feinberg J; Katakam KK; Fobian K; Hauser G; Poropat G; Djurisic S; Weiss KH; Bjelakovic M; Bjelakovic G; Klingenberg SL; Liu JP; Nikolova D; Koretz RL; Gluud C
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD012143. PubMed ID: 28922704
[TBL] [Abstract][Full Text] [Related]
4. Drug-Drug Interactions Potential of Direct-Acting Antivirals for the treatment of Chronic Hepatitis C Virus infection.
Néant N; Solas C
Int J Antimicrob Agents; 2020 Jul; 56(1):105571. PubMed ID: 30394302
[TBL] [Abstract][Full Text] [Related]
5. Focus on drug interactions: the challenge of treating hepatitis C virus infection with direct-acting antiviral drugs in the HIV-positive patient.
Rodríguez-Torres M
Curr Opin Infect Dis; 2013 Feb; 26(1):50-7. PubMed ID: 23242341
[TBL] [Abstract][Full Text] [Related]
6. Key drug-drug interactions with direct-acting antiviral in HIV-HCV coinfection.
El-Sherif O; Khoo S; Solas C
Curr Opin HIV AIDS; 2015 Sep; 10(5):348-54. PubMed ID: 26248122
[TBL] [Abstract][Full Text] [Related]
7. Comedications and potential drug-drug interactions with direct-acting antivirals in hepatitis C patients on hemodialysis.
Hsu PY; Wei YJ; Lee JJ; Niu SW; Huang JC; Hsu CT; Jang TY; Yeh ML; Huang CI; Liang PC; Lin YH; Hsieh MY; Hsieh MH; Chen SC; Dai CY; Lin ZY; Chen SC; Huang JF; Chang JM; Hwang SJ; Chuang WL; Huang CF; Chiu YW; Yu ML
Clin Mol Hepatol; 2021 Jan; 27(1):186-196. PubMed ID: 33317251
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of a specialty hepatitis C virus telephone pharmacy service.
Sabourin AA; Fisher-Grant KK; Saulles AR; Mohammad RA
Am J Health Syst Pharm; 2021 May; 78(Supplement_2):S38-S45. PubMed ID: 33684928
[TBL] [Abstract][Full Text] [Related]
9. Managing drug-drug interactions with new direct-acting antiviral agents in chronic hepatitis C.
Talavera Pons S; Boyer A; Lamblin G; Chennell P; Châtenet FT; Nicolas C; Sautou V; Abergel A
Br J Clin Pharmacol; 2017 Feb; 83(2):269-293. PubMed ID: 27530469
[TBL] [Abstract][Full Text] [Related]
10. In Vitro Assessment of Transporter Mediated Perpetrator DDIs for Several Hepatitis C Virus Direct-Acting Antiviral Drugs and Prediction of DDIs with Statins Using Static Models.
Chu X; Chan GH; Houle R; Lin M; Yabut J; Fandozzi C
AAPS J; 2022 Mar; 24(3):45. PubMed ID: 35314909
[TBL] [Abstract][Full Text] [Related]
11. Drug-Drug Interactions Between Direct-Acting Antivirals and Psychoactive Medications.
Smolders EJ; de Kanter CT; de Knegt RJ; van der Valk M; Drenth JP; Burger DM
Clin Pharmacokinet; 2016 Dec; 55(12):1471-1494. PubMed ID: 27317413
[TBL] [Abstract][Full Text] [Related]
12. Directly acting antivirals for hepatitis C and antiretrovirals: potential for drug-drug interactions.
Seden K; Back D
Curr Opin HIV AIDS; 2011 Nov; 6(6):514-26. PubMed ID: 22001895
[TBL] [Abstract][Full Text] [Related]
13. Direct antiviral agents (DAAs) and their use in pregnant women with hepatitis C (HCV).
Abdul Massih S; Eke AC
Expert Rev Anti Infect Ther; 2022 Nov; 20(11):1413-1424. PubMed ID: 36111676
[TBL] [Abstract][Full Text] [Related]
14. Drug-Drug Interactions of Newly Approved Direct-Acting Antiviral Agents in Patients with Hepatitis C.
Gao LH; Nie QH; Zhao XT
Int J Gen Med; 2021; 14():289-301. PubMed ID: 33536776
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic Intervention of Serine Protease Inhibitors against Hepatitis C Virus.
Kamal S; Shahzad A; Rehman K; Tariq K; Akash MSH; Imran M; Assiri MA
Curr Med Chem; 2024; 31(15):2052-2072. PubMed ID: 37855348
[TBL] [Abstract][Full Text] [Related]
16. Recent Advancement of Direct-acting Antiviral Agents (DAAs) in Hepatitis C Therapy.
Das D; Pandya M
Mini Rev Med Chem; 2018; 18(7):584-596. PubMed ID: 28901852
[TBL] [Abstract][Full Text] [Related]
17. Frequency of Potential Drug-Drug Interactions in the Changing Field of HCV Therapy.
Schulte B; Wübbolding M; Marra F; Port K; Manns MP; Back D; Cornberg M; Stichtenoth DO; Höner Zu Siederdissen C; Maasoumy B
Open Forum Infect Dis; 2020 Feb; 7(2):ofaa040. PubMed ID: 32104719
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis C Direct-Acting Antiviral Treatment Selection, Treatment Failure, and Use of Drug-Drug Interactions in a State Medicaid Program.
Keast SL; Holderread B; Cothran T; Skrepnek GH
J Manag Care Spec Pharm; 2019 Nov; 25(11):1261-1267. PubMed ID: 31663456
[TBL] [Abstract][Full Text] [Related]
19. Treatment of chronic HCV genotype 1 coinfection.
Boesecke C; Rockstroh JK
Curr HIV/AIDS Rep; 2015 Sep; 12(3):326-35. PubMed ID: 26228050
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Drug-Drug Interactions Between Hepatitis C Antiviral Agents Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and HIV-1 Protease Inhibitors.
Khatri A; Dutta S; Wang H; Podsadecki T; Trinh R; Awni W; Menon R
Clin Infect Dis; 2016 Apr; 62(8):972-9. PubMed ID: 26740513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
